The short version of Peptide stability fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-06. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
=== Identification / Quantification === The detection of herbal toxins has generally caused a diagnostic problem due to wide variety of plants and limited standard screening. For a long time, the identification of ATR poisoning was limited to postmortem analysis of one's kidneys or liver. Subsequent developments made to identify the presence of ATR in bodily fluids (blood or urine) only worked with high concentrations of ATR. Now, more recent research has established the necessary sensitivity and specificity to be applied to forensic toxicology. The development of the below procedure relied on findings from unsuccessful methods of identification, primarily traced to the following literature in which the specificity and sensitivity was improved over time. Due to the limited research on the subject of ATR identification, this literature represents the primary sources to review:
=== Collagen === Lin and her lab use molecular dynamics simulations to understand how the structure, stability, and interactions of collagen are perturbed by Gly to Ser substitutions, a very common type of Gly missense mutations in patients with Osteogenesis Imperfecta (OI), and Ser phosphorylation. Their results suggest a new possible mechanism underlying OI pathology, specifically that mutations may significantly disrupt the triple-helical structure of collagen and render it susceptible to non-collagenase proteolytic enzymes.
=== Mixed martial arts === Ultimate Fighting Championship Fight of the Night (Two times) vs. Joanne Calderwood and Seo Hee Ham Performance of the Night (One time) vs. Mara Romero Borella Tied (Angela Hill, Jorge Masvidal, Clay Guida, Paul Felder & Andrea Lee) for most split decision losses in UFC history (4)
Sources: en.wikipedia.org
In 2008, she co-founded Hepregen, based on her microliver technology for drug testing. Hepregen was acquired by BioIVT in 2018. In 2015, Bhatia spun off Glympse Bio based on her activity-based nanosensor technology. Glympse Bio received significant funding to advance "activity sensors" for diagnosis and therapy selection, completing safety studies in human volunteers before merging with Sunbird Bio in 2023. She has also co-founded other startups, notably Satellite Bio (microliver "satellite" technology with Christopher Chen), Port Therapeutics (along with Gabe Kwong and Mikhail Shapiro), Impilo Therapeutics (with Erkki Ruoslahti, Frank Slack, and Michael Sailor; the company was acquired by Lisata Therapeutics in 2020), Ropirio Therapeutics (with Christopher Chen), Matrisome Bio (with Richard Hynes), and Amplifyer Bio (with J. Christopher Love, Viktor Adalsteinsson, and Todd Golub). Bhatia is a passionate advocate for gender equity and inclusivity in STEM fields. She co-founded the MIT Faculty Founders Initiative with MIT Professor and President Emerita Susan Hockfield and MIT Amgen Professor of Biology Emerita Nancy Hopkins. This initiative aims to address the significant disparity in the number of female academics in science and engineering who become entrepreneurs. Their research revealed that women had founded less than 10% of the 250 biotech startups created by MIT professors, despite women comprising 22% of the MIT faculty. Her dedication to diversity extends to:
=== Psychological motivations === Psychology is another factor to take into consideration in doping in sport. It becomes a behavioral issue when the athlete acknowledges the health risks associated with doping, yet participates in it anyway. This has to do with the psychological thinking that the drug will make one feel invincible. The individuals are very egotistic in their way of thinking and their motivation is dependent on the performance enhancement drug since they believe that it delivers the results. On a study on health psychology, Quirk points out three different psychological aspects that lead one to dope: social cognition, stress and strain, and addiction. The social and physical pressures can alter an athlete's way of thinking, leading them to believe that they must take performance enhancement drugs since everyone else is doing it, known as "the doping dilemma." This also causes athletes to be hesitant to consult with a doctor about their steroid use, putting themselves at more risk with health problems.
On September 25, Xi and Peng returned to the White House with Donald and Melania Trump. They then attended a tea ceremony in the Red Room. Trump said US farmers "are going to be very happy" with the talks, adding "A lot of very positive things happened, but America is very happy about this visit and I’m sure China is very happy also". He said "We’ve had a tremendous visit from two spectacular people" and "We’ve really enjoyed it and I think we’ve been tremendous strides. We’ve made great strides, very positive for both countries." During this tea ceremony, Xi said that he and Trump "are like two people who are charting the course for the great ship of China-U.S. relations." Xi also confirmed that two leaders will to see each other later this year in twice, including APEC summit in Shenzhen and G20 Summit in Miami. Later, Xi and Trump visited the National Archives, and viewed the Declaration of Independence, the Constitution and the Bill of Rights. According to the NPR, a table that included a temporary display showcasing a brick from the Great Wall of China and an 19th century scroll sent by a Qing emperor was removed because the display also planned to show the Treaty of San Francisco, which China considers as illegitimate because it was not a signatory. Other documents, including Six Assurances and the Three Communiqués, were also discussed for display, but ultimately not included.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.